FDA Accepts New Drug Application for Novel Glaucoma Eye Drop NCX 470

The U.S. FDA accepted the NDA for NCX 470 (bimatoprost grenod, also known as K-911) on October 10, 2026, marking a regulatory milestone for a first-in-class nitric oxide-donating prostaglandin analogue targeting intraocular pressure reduction in glaucoma.

Key Details

NCX 470 combines a prostaglandin analogue with a nitric oxide-donating moiety, potentially offering enhanced IOP-lowering via dual mechanisms (uveoscleral outflow and trabecular meshwork relaxation). Kowa Company submitted the application and holds U.S./Japan/global rights; Ocumension holds China/Korea/Southeast Asia rights. PDUFA date: April 30, 2027.

Why It Matters

If approved, NCX 470 would be the first nitric oxide-donating prostaglandin for glaucoma, a condition affecting over 80 million people globally. The dual-mechanism approach addresses limitations of current prostaglandin monotherapy.

Context

Nicox (developer) expects U.S. launch in H2 2027 pending approval. No Australian or New Zealand filing announced. The acceptance follows positive phase 3 data showing statistically significant IOP reduction versus latanoprost.